皓宸医疗
(002622)
| 流通市值：17.89亿 | | | 总市值：17.89亿 |
| 流通股本：8.40亿 | | | 总股本：8.40亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 520,430,368.51 | 314,060,723.5 | 134,804,640.83 | 702,897,591.79 |
| 营业收入 | 520,430,368.51 | 314,060,723.5 | 134,804,640.83 | 702,897,591.79 |
| 二、营业总成本 | 510,322,721.34 | 319,756,039.49 | 145,564,795.01 | 766,396,075.56 |
| 营业成本 | 240,920,504.32 | 150,018,256.98 | 69,227,179.55 | 389,482,401.23 |
| 税金及附加 | 1,592,897.81 | 991,456.39 | 485,604.56 | 2,443,714.65 |
| 销售费用 | 123,635,839.83 | 76,176,850.64 | 33,960,154.39 | 176,214,408.51 |
| 管理费用 | 107,161,049.35 | 68,939,804.58 | 30,419,067.1 | 146,007,181.93 |
| 研发费用 | 9,236,143.91 | 5,166,336.39 | 1,993,188.74 | 11,755,288.49 |
| 财务费用 | 27,776,286.12 | 18,463,334.51 | 9,479,600.67 | 40,493,080.75 |
| 其中:利息费用 | 27,374,094.49 | 18,433,383.19 | 9,273,840.58 | 40,013,214.12 |
| 其中:利息收入 | 1,205,116.24 | 955,729.49 | 173,599.26 | 585,214.84 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 163,372.38 | 163,372.38 | 163,372.38 | -1,076,444.51 |
| 资产处置收益 | 513,096.16 | -202.01 | - | 710,274.09 |
| 资产减值损失(新) | - | - | - | -54,379,889.42 |
| 信用减值损失(新) | 781,012.51 | 1,288,493.66 | 894,751.36 | 2,120,652.6 |
| 其他收益 | 3,161,674.87 | 2,283,714.64 | 2,141,846.85 | 4,543,725.19 |
| 四、营业利润 | 14,726,803.09 | -1,959,937.32 | -7,560,183.59 | -111,580,165.82 |
| 加:营业外收入 | 854,135.63 | 122,944.05 | 88,018.24 | 769,864.96 |
| 减:营业外支出 | 797,645.79 | 574,664 | 222,507.63 | 15,108,218.82 |
| 五、利润总额 | 14,783,292.93 | -2,411,657.27 | -7,694,672.98 | -125,918,519.68 |
| 减:所得税费用 | 5,460,112.82 | 2,933,790.87 | 953,535.9 | 4,006,754.32 |
| 六、净利润 | 9,323,180.11 | -5,345,448.14 | -8,648,208.88 | -129,925,274 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 9,323,180.11 | -5,345,448.14 | -8,648,208.88 | -129,925,274 |
| 终止经营净利润 | - | 0 | - | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -12,236,579.81 | -14,025,923.8 | -8,340,483.51 | -119,422,451.09 |
| 少数股东损益 | 21,559,759.92 | 8,680,475.66 | -307,725.37 | -10,502,822.91 |
| 扣除非经常损益后的净利润 | -12,834,983.19 | -14,113,056.61 | -8,423,371.58 | -106,426,656.37 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.01 | -0.02 | -0.01 | -0.14 |
| (二)稀释每股收益 | -0.01 | -0.02 | -0.01 | -0.14 |
| 八、其他综合收益 | 4,255,945.65 | 4,255,971.08 | 4,256,010.48 | -6,793,700.91 |
| 归属于母公司股东的其他综合收益 | 4,255,945.65 | 4,255,971.08 | 4,256,010.48 | -6,793,700.91 |
| 九、综合收益总额 | 13,579,125.76 | -1,089,477.06 | -4,392,198.4 | -136,718,974.91 |
| 归属于母公司股东的综合收益总额 | -7,980,634.16 | -9,769,952.72 | -4,084,473.03 | -126,216,152 |
| 归属于少数股东的综合收益总额 | 21,559,759.92 | 8,680,475.66 | -307,725.37 | -10,502,822.91 |
| 公告日期 | 2026-10-30 | 2026-08-26 | 2026-04-29 | 2026-04-29 |
| 审计意见(境内) | | | | 保留意见 |